Glofitamab in Chinese Patients With R/R DLBCL

Sponsor
Peking Union Medical College Hospital
Study ID
NCT06481826
Status
Recruiting
Apply to this trial

Conditions

  • DLBCL - Diffuse Large B Cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Glofitamab — DRUG
    Glofitamab given in standard dosage

Study Details

This study will evaluate the safety and efficacy of glofitamab as a single agent in Chinese patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have failed two or more lines of systemic therapy.

Key Dates

Start date
Jan 1, 2024
Status verified
Mar 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
20 participants (estimated)

Arms

  • Arm: treatment group
    Glofitamab

Primary Outcome Measure

PFS [ Time Frame: 1 year ]

Central Contacts

Related Studies